Most CHOICES patients qualify for financial assistance. Learn more about our Patient Discount Fund HERE.

CHOICES Responds to SCOTUS Decision FDA v. AHM

CHOICES Center For Reproductive Health Early Option Pill Mifepristone

CHOICES Responds to SCOTUS Decision FDA v. AHM

CHOICES is relieved that the Supreme Court has voted to dismiss the challenge against mifepristone on a lack of standing. Mifepristone is a safe, effective FDA-approved medication used in combination with misoprostol to induce a medical abortion. Medication abortions currently account for more than sixty percent of abortions in the United States. 

While this is a relief, this case should have never reached our highest court. Our right to access abortion will continue to be threatened by policymakers, and we will remain vigilant. CHOICES will continue to provide compassionate, evidence-based care to all individuals.  Since opening our clinic in Southern Illinois, we have provided over 5,000 abortions to primarily folks from Tennessee, Mississippi, and Arkansas. The overwhelming majority of our patients choose medication abortion because it is safe, minimally invasive, and can be done in the comfort of their homes with their support systems. With this ruling, our patients will still have access to the medication they need and deserve. 

“This ruling is the correct decision, reaffirming the FDA’s rigorous medication approval process and respecting the autonomy of abortion providers in guiding medical decisions. The case, brought forward by plaintiffs with no legal standing or genuine concern for patient safety, was a blatant attempt to further an agenda to ban all abortion. Mifepristone has over twenty years of proven safety and efficacy, whether provided in-clinic, via telehealth, or self-managed by patients. CHOICES, alongside other abortion care providers, remains committed to ensuring that all individuals have equal and just access to abortion care, free from judgment and shame,”  says Jennifer Pepper, CHOICES’ President & CEO.

Facebook
Twitter
LinkedIn